Short answer
Maze Therapeutics, Inc. (MAZE) filed an 8-K current report with the SEC on October 16, 2026 reporting Item 3.02 (Unregistered Sales of Equity Securities), Item 1.01 (Entry into a Material Definitive Agreement). Item 1.01 points investors to Item 3.02 for the substantive transaction details.
Maze Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Item 1.01 points investors to Item 3.02 for the substantive transaction details
- Material agreement implications depend on the securities issuance or funding terms described under Item 3.02
Item 3.02 · Unregistered Sales of Equity Securities
- Maze exchanged 2,776,007 common shares for pre-funded warrants exercisable at $0.001 per share
- Outstanding shares decreased to 53,931,889 after the exchange, reducing immediately outstanding equity
- Warrants remain exercisable anytime, subject to a 9.99% beneficial-ownership cap
- Exchanging holders lack voting rights on underlying shares except where Delaware law requires them
- Transaction completed without Securities Act registration under Section 3(a)(9) exemption
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Maze Therapeutics, Inc. 8-K filings
Get the next MAZE 8-K as it lands
Follow MAZE for push alerts, or ask the research agent what this filing means.